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The skeleton in diabetes – involvement and interaction
Abstract
Diabetes mellitus (DM) is characterized by high blood glucose; impair-
ment of the skeleton is among its other deleterious effects. Adverse effect upon 
the bone tissue is primarily altered bone quality and consequently increased 
bone fragility. In DM 1, bone mass may be low and in DM2 normal or 
even increased. Therapy for DM2 also affects bone metabolism as thiazoli-
dine-diones cause differentiation shift of mesenchyme precursors from osteo-
blasts into adipocytes. Association of bone with glucose metabolism was 
discovered in the last decade indicating that insulin is necessary for synthesis 
of undercarboxylated osteocalcin which acts in a hormonal fashion to pro-
mote insulin secretion in the pancreas, adiponectin in adipocytes, and in-
creases insulin sensitivity in target tissues. Undercarboxylated osteocalcin is 
also secreted from resorbed bone. Thus insulin is required for normal bone 
metabolism and bone acts as an endocrine organ. Additional role of osteo-
calcin is in promoting testosterone secretion in testes.
IntroductIon
Diabetes mellitus (DM, both type 1 and 2) has long been recognized as disease which affects skeletal integrity. Although different eti-
ologies and disease mechanisms are involved in diabetes type 1 and 2, 
certain similarities regarding the outcome upon skeleton exist, i.e. great-
er bone fragility and greater risk of fractures, and this includes also 
hypovitaminosis D. The common mechanism of impaired mineral me-
tabolism includes hyperglycemia which contributes to increased urine 
calcium excretion, poor bone quality due to formation of advanced gly-
cosylation end products that permanently affect bone matrix, low bone 
turnover, increased bone fragility and increased fracture risk arising 
from altered bone quality. The differences in etiologies of DM1 and 
DM2 are also reflected on their effect upon bone metabolism. The onset 
of DM1 is usually at an earlier age and very likely to affect achievement 
of peak bone mass with low bone mass. In DM1, lack of insulin affects 
all aspects of development and growth. Body mass index may also be 
low in these patients, with low muscle mass and low fatty tissue which 
both have a negative impact upon peak bone mass and its maintenance. 
In patients with DM2 with predominantly late onset, bone mass may 
be normal or even increased (1, 2).
The underlying disorder of DM2 is insulin resistance and hyperinsu-
linemia. As insulin is an anabolic agent, together with increased IGF1, 
insulin contributes to bone mass accrual. Increased body mass, very 
frequent in DM2 patients, also favors bone mass preservation. Hypovi-
taminosis D which is common in both DM1 and DM2 may be due to 
general poor health and compromised quality of life in particular in 
DM1 patients whose glucose levels are not optimally controlled. Vitamin 
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D sequestration in fatty tissue in both DM1 and DM2 
patients is recognized as additional risk for skeletal impair-
ment. Bone quality in DM2 deteriorates as indicated by 
increased fractures of the hip and spine despite preserved 
bone mass (3). Assessment of skeletal features, including 
bone quality and not only bone mass, will become a pre-
rogative in monitoring and treating DM2 patients as DM 
2 incidence is increasing in aging societies and requiring 
also fracture risk assessment. Basic characteristics regard-
ing skeletal involvement in DM1 and DM2 are summa-
rized in Table 1.
AssocIAtIon of bone And energy 
metAbolIsm
It was the crucial discovery of Lee et al reported in 
2007 (4) which brought a new insight of association of 
bone metabolism and energy homeostasis (Figure 1). Os-
Table 1
Summarized features of DM1 and DM2 regarding skeletal involvement.
DM1 DM2
Endocrine mechanism Insulin deficiency, hyperglycemia Insulin resistance, increased IGF1, hyperglycemia
Age of onset young mature, old
Body mass low increased
Skeletal impairment
affect peak bone mass, bone mass low, bone turnover 
low, altered bone quality, increased risk of fractures, 
increased calcium excretion due to hyperglycemia, 
hypovitaminosis D
bone mass normal or increased, bone turnover low, 
altered bone quality, increased risk of fractures, 
increased calcium excretion due to hyperglycemia, 
hypovitaminosis D
Involvement of other 
systems
deleterious effect on blood vessels, neuropathy, visual 
impairment, kidney function deterioration
deleterious effect on blood vessels, neuropathy, 
visual impairment, kidney function deterioration
 
Table 2
Reports on association of skeletal metabolism with glucose metabolism.
Reference Observation Subjects/patients
36 Negative correlation of osteocalcin and blood glucose and parameters of atherosclerosis DM2 adults
37 Negative correlation of undercarboxylated osteocalcin and blood glucose and fat mass, posi-tive with adiponectin DM2
38 Negative correlation of osteocalcin and blood glucose and fat mass non-diabetic
39 Positive correlation of osteocalcin and insulin sensitivity, increase of osteocalcin after weight loss obese adults
8 Negative correlation of osteocalcin with fasting glucose and insulin, insulin resistance, C-reactive protein, IL-6, BMI and fat mass; osteocalcin associated with change in blood glucose DM2
40 Lower levels of osteocalcin in diabetics which increased with glycemic improvement healthy and diabetics
41 Increase in undercarboxylated osteocalcin as a result of aerobic exercise obese and diabetic men
42 Increase of osteocalcin, decrease of leptin and improvement of insulin sensitivity after weight loss obese children
43 Positive correlation of osteocalcin and adiponectin DM2
44 Positive correlation of undercarboxylated osteocalcin and adiponectin postmenopausal women
45 No difference in undercarboxylated osteocalcin DM1 and controls
46 Undercarboxylated osteocalcin positive correlated with insulin healthy children
teocalcin, i.e. undercarboxylated osteocalcin was recog-
nized as a key factor in coupling of these otherwise diverse 
systems. Conclusions of Karsenty’s group on new aspects 
of glucose metabolism which were consistent with reports 
of other investigators on glucose, osteocalcin, adiponec-
tin, fat mass and other factors in humans, have so far 
enabled new concepts of the entire metabolism (4). In 
summary, insulin acting through its receptor on osteo-
blasts activates protein tyrosine phosphatase (in humans 
protein tyrosine phosphatase 1B) to produce undercar-
boxylated osteocalcin as opposed to osteocalcin with post-
translational three glutamic acid residues. This modifica-
tion of osteocalcin is important because of its calcium 
binding properties. Thus osteocalcin containing glutam-
ic acid residues has high affinity for bone matrix. Decar-
boxylation reduces the affinity of osteocalcin (undercar-
boxylated osteocalcin) for hydroxyapatite in bone matrix. 
This process occurs during bone resorption. This form of 
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osteocalcin, i.e. the undercarboxylated osteocalcin, is the 
active or hormonal form as it promotes insulin synthesis 
and secretion in pancreatic beta cells and adiponectin se-
cretion from adipocytes. Additionally, insulin sensitivity 
is improved, energy expenditure increased and fat mass 
decreased. The regulation goes through ESP gene which 
encodes for the protein tyrosine phosphatase, and leptin 
also acts to increase its action with resulting secretion of 
osteocalcin with three glutamic residues, i.e. the non-ac-
tive osteocalcin (or the non-hormone form). Leptin also 
decreases insulin secretion in the pancreas. Undercarbox-
ylated osteocalcin is also released from bone matrix dur-
ing bone resorption, as insulin inhibits osteoprotegerin 
synthesis and thus promotes osteoclast bone degradation. 
The work of Lee et al. (4) will probably require a change 
in the traditional concept of endocrinology as the skeleton 
or bone tissue becomes an endocrine organ involved in 
regulation of energy metabolism.
This brings new light to understanding skeletal in-
volvement in diabetes. In DM1 with impaired insulin 
secretion, opposite metabolic effects are observed com-
pared to those described previously for the normal insulin 
secretion. Also, insulin deficiency is the cause of low os-
teocalcin synthesis and poor bone formation, with the 
result of low bone mass and impaired bone quality. In 
rodents, low osteocalcin is also associated with low testos-
terone synthesis in testicular Leydig cells, but it appar-
ently lacks a similar effect on ovaries.
Endocrine interaction of bone (i.e. osteoblasts) and 
energy metabolism (i.e. pancreas) includes two counter-
acting key factors: leptin (the bad guy) and insulin (the 
good guy). Insulin signalling in osteoblasts is regulated 
through its receptor tyrosin kinase, a substrate of tyrosine 
phosphatase (encoded by ESP gene) (2). Binding of insu-
lin to its osteoblast receptor results in decrease of osteo-
protegerin secretion. This alters the balance of osteoblast-
osteoclast cross-talk and enables osteoclast activity. Bone 
resorption and acidification of bone microenvironment 
releases decarboxylated osteocalcin from bone matrix into 
extracellular fluid. Body fluids and plasma contain both 
carboxylated and undercaboxylated osteocalcin. Bone 
resorption favors decarboxylation of osteocalcin by creat-
ing acidic environment. Release of osteocalcin and its 
decarboxylation yield undercaboxylated osteocalcin 
which acts as a hormone on the pancreas, adipose tissue, 
liver and the testes (4). In adolescent boys, a positive as-
sociation between osteocalcin and testosterone would 
tradionally be attributed to pubertal growth spurt. Pu-
berty is characterized by several-fold higher levels of bone 
markers, both formation and resorption markers, as com-
pared to adults. Bone markers reflect intensive and ac-
celerated bone growth during puberty which will level-off 
toward adulthood, i.e. approximately toward the twenties. 
With regard to new data on bone and gonads, it can be 
speculated that this association of osteocalcin and testos-
terone also reflects a direct interaction of the endocrine 
bone and gonad function (5).
Data on clinical studies supporting causative relation-
ship between different aspects of bone metabolism and 
glucose homeostasis are summarized in Table 2. These 
results also indicate the key role of osteocalcin (or rather 
undercaboxylated osteocalcin) in coupling bone and en-
ergy metabolism (6).
Systemic administration of undercarboxylated osteo-
calcin in experimental models has anti-diabetic properties 
by lowering blood glucose, increasing insulin secretion 
and insulin sensitivity of target tissues (muscle, adipose 
tissue, and liver) (7). In experimental animal models (pri-
marily rodents), gross alterations of osteocalcin and un-
dercarboxylated osteocalcin were reported. In studies on 
humans, the differences are mostly within a normal phys-
iological range and correlations with fasting glucose and 
insulin sensitivity were reported. Not surprisingly, diabe-
tes in humans is associated with lower total osteocalcin. 
In clinical studies, improved glycemic control have re-
sulted in higher osteocalcin levels. More human studies 
are necessary to confirm the results obtained in animal 
studies. For example, studies in patients where effects of 
undercarboxylated osteocalcin or osteocalcin on glucose 
metabolism were investigated have provided conflicting 
results. In some studies (8), improved fasting glucose 
could be predicted, but in others (9) (with vitamin K 
supplementation for decrease of undercaboxylated osteo-
calcin) opposite results were found on insulin sensitivity 
compared to those predicted from rodent models.
Figure 1. Presentation of interaction of bone metabolism and glucose 
regulation. Insulin promotes secretion of undercarboxylated osteo-
calcin in osteoblasts, which in turn stimulates insulin secretion in 
the pancreas, adiponectin in adipose tissue and energy expenditure, 
improves insulin sensitivity in target tissues and blocks osteoprote-
gerin synthesis with increased bone resorption and release of decar-
boxylated osteocalcin. Also, testesterone synthesis is stimulated in 
the Leydig cells of testes. Insulin deficiency has opposite effects, in-
cluding poor osteocalcin synthesis and low bone mass.
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bone In dIAbetes – frAgIlIty And 
frActure rIsk
Bone fragility and risk of fractures with its conse-
quences on life-style and independence is an important 
problem of aging population with increasing incidence of 
DM2. Bone loss occurs with aging in both men and 
women. This is more pronounced in postmenopausal 
women with accelerated bone loss after cessation of ovar-
ian estrogen production. At an advanced age, the rate of 
bone loss is similar for both sexes. However, females are 
at a disadvantage compared to males because peak bone 
mass is less and postmenopausal bone loss occurs at an 
increased rate. Osteoporosis in older population is thus 
frequent, affecting approximately 15% of women and 5% 
of men older than 50 years. It is well established that bone 
mass, measured by the standard method of dual-photon 
densitometry, is highly related to fracture risk (10).
Skeletal integrity is impaired in diabetes; this applies 
to both types 1 and 2 and was established long ago. It is 
a serious health problem for diabetic patients because frac-
ture risk increased and has consequences for individual 
patients and the entire community. In particular, studies 
have reported an increased risk of hip fractures which are 
particularly deterimental in older people, resulting in dis-
ability and even death from multi-organ failure.
Aging population is also affected by greater DM2 in-
cidence, and both DM2 and also DM1 are characterized 
by increased fracture risk. Bone mass in DM2 is not nec-
essarily decreased; on the contrary, it may be normal or 
increased but bone fractures occur despite evidence of 
non-compromised bone mass. The problem is in altered 
bone quality, a feature not assessed by densitometry 
which, in fact, measures bone mineral content. This was 
observed and reported for both the hip, vertebral and foot 
fractures in DM2 (11). In the case of DM2, the associa-
tion of bone mineralization and fragility is not reliable for 
prediction of fracture risk. An apparent paradox is that 
greater risk of fracture in diabetics does not correspond 
to low BMD as it does in healthy population. Although 
BMD in DM1 patients is lower than in general popula-
tion, the actual densitometry measurements do not ac-
count for this high fracture risk. In contrast, BMD is in 
DM2 patients better than in non-diabetic populationl i.e. 
densitometry results are higher, but fractures occur with 
increased frequency (12). This was not a universal obser-
vation and some investigators have found fracture risk to 
be similar to that (13, 14) in normal population.
In DM1, increased risk was found for hip fractures (11), 
but also for the spine and humerus (15). Epidemiological 
studies have indicated that the main cause of increased 
fracture risk in diabetes both type 1 and 2 is altered bone 
quality, and not decreased bone quantity. Poor bone qual-
ity also leads to fractures. Increased blood glucose in inef-
ficient glycemic control generates advanced glycation end 
products which permanently alter bone matrix structure, 
among other tissues. Thus, bone quality deteriorates by 
accumulation of advanced glycation end products, its in-
tegrity is not any more intact and fragility is increased. 
These compounds adversely affect collagen, osteocytes, 
and multipotent bone marrow stem cells (16, 17, 18).
Prolonged exposure to hyperglycemia and to the det-
rimental effects of advanced glycation end products on 
bone resulted in an increment in fracture risk that was 
reported approximately 12–14 years after the diagnosis of 
diabetes (11,19).
Established therapy for blood glucose control in DM2 
also contributes to secondary osteoporosis. The mecha-
nism is based on altered bone remodeling balance with 
decreased bone formation and increased bone resorption. 
Advanced age and postmenopause are additional adverse 
risk factors contributing to osteoporosis and fracture risk.
Evidence from retrospective clinical studies have con-
firmed adverse effect of thiazolidine-diones in DM2, with 
emphasis on increased bone loss and risk of fractures in 
elderly women, although according to some studies with 
equal risk for both sexes, increased risk in patients with 
previous fracture history and positive correlation with 
duration of treatment.
Regarding bone safety in DM2 patients, combination 
therapy with other antidiabetic therapies or preventing 
further bone loss by administration of antiresorptive/ an-
tiosteoporotic drugs might be an option to preserve skel-
etal integrity. An established and effective therapy for 
normalization of blood glucose in DM2 are thiazolidine-
diones. These compounds act on peroxisome proliferator-
activated receptor-g (PPAR-g) protein, a key regulator of 
energy metabolism in fat tissue. However, the disadvan-
tage is that PPARg also interacts with bone cell prolifera-
tion and differentiation and the cytokine composition in 
the bone marrow extracellular fluid. Thiazolidine-dione 
in in-vitro studies and animal models probably acts on 
pluripotent mesenchymal stem cells in the bone marrow, 
shifting differentiation towards adipocyte precursors at 
the expense of osteoblast precursors (20).
Bone marrow space is filled with adipose tissue, bone 
turnover, i.e. regeneration, is impaired and bone loss results 
(21,22). This also depletes the recruitment into osteoblasts, 
adversely affecting bone turnover. PPAR-g can regulate 
synthesis of many cytokines which support the hematopoi-
etic-macrophage lineage, i.e. it supports osteoclastogenesis 
and bone resorption. Unfortunately, this needs to be con-
firmed in human studies, and other potential mechanisms, 
including an indirect negative effect on osteoblasts via en-
hanced secretion of adipocyte factors, remain to be eluci-
dated. Also, an important aspect is the possible confound-
ing effect of thiazolidine-diones on fracture healing (20).
There are more adverse effects of diabetes besides mod-
ifications of bone matrix due to advanced glycation end 
products. Mineralization of bone matrix may also be af-
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fected. Additional risk factors for fractures in patients with 
diabetes include systemic consequences of uncontrolled 
glycemia which affect the nervous system, vision, kidney 
function and other systems, all contributing to risk of falls 
and poor bone healing. Diabetic neuropathy and neuro-
muscular impairment are major risk factors for falls (23). 
Severe hypoglycemia in patients on insulin therapy should 
also be considered a risk factor contributing to dizziness 
and falls.
obesIty In dIAbetes – endocrIne 
And other effects
Obesity is not only a feature of DM2, but also a glob-
al epidemic of the Western world with affordable access 
to high calorie food and sedentary lifestyle. Body fat has 
an endocrine effect on the skeleton by secreting adipo-
kines. For example, leptin – besides its effect on appetite 
and reproduction – acts centrally on the sympathetic ner-
vous system and hypothalamic neurons, and has negative 
impact on bone mass by inhibiting bone accrual.
The pathway of central leptin effect is common to se-
rotonin. Actually, leptin inhibits serotonin synthesis 
which in turn stimulates signalling of the sympathetic 
nervous system, and finally acting of beta adrenergic re-
ceptors on osteoblasts. Dual pathway acts by inhibition 
of osteoblast proliferation and also by promoting RANKL 
expression and osteoclast activation. Leptin also has pe-
ripheral anabolic action on bone mass, stimulating osteo-
blasts and inhibiting osteoclasts. The alternate pathway is 
through receptors of the arcuate nucleus neurons by in-
creasing CART (cocaine and amphetamine regulated 
transcript) gene expression and further decreasing 
RANKL expression on osteoblasts (2,3).
Fatty tissue and its mass has long been established as a 
protective factor for bone mass, with main effect attributed 
to conversion of androgens into estrogens by an aromatase. 
The sheer weight of greater body mass is not a significant 
contributor to skeletal health. Adipose tissue has less spe-
cific weight in comparison to muscle tissue and thus pro-
portionally has less impact. The effect of skeletal muscles, 
i.e. muscle contraction and strain during exercise, will exert 
considerable force on the bone. This change and increment 
of pressure-pull forces promote bone remodeling and bone 
formation, with the main goal of achieving a new biome-
chanical steady state with optimal force distribution 
(10,24). Modification of muscle work or exercise program 
can progressively stimulate further bone remodeling and 
bone growth to adapt to new and increasing load. Increased 
body weight in obese has a less pronounced beneficial effect 
upon the skeleton. Another recognized benefit, but of lim-
ited value, is the cushion effect of fatty tissue. These ben-
efits are of moderate influence as mobility is with increas-
ing body weight progressively hampered and muscle action 
on the skeleton reduced. Deleterious effects of obesity on 
other systems, e.g. cardiovascular, renal, locomotor and 
other, are well established.
Low body weight is a recognized risk factor for bone 
fracture, and obesity is characterized by high cortical 
bone mass. It is well known that adipose tissue insulates 
the skeleton, but also exerts increased load on the skeleton 
with enhanced mechanical signalling to osteocytes and 
the cortical bone. Also, excess body weight may be detri-
mental to the skeleton. Diseases associated with aging, 
e.g. metabolic syndrome and insulin resistance, are also 
linked to fragility fractures (10,24). Patients with DM1 
and DM2 differ regarding body weight and accordingly 
in body mass index. These two disorders differ greatly in 
hormonal profiles. DM1 is characterized by insulin defi-
ciency, low IGF1 and steroid hormones, while in DM2 
there is increased insulin secretion, high estrogens and 
androgens, and normal IGF1 (3).
the role of vItAmIn d
Vitamin D deficiency has been recognized almost as 
an epidemic ever since rapid and convenient measurement 
methods have become available. It is estimated that ap-
proximately 30-50% of children and adults are vitamin 
D-deficient with regard to concentration of 50 nmol/L 
for 25-hydroxyvitamin D in blood (25). This is the level 
of deficiency (or insufficiency) of 25-hydroxyvitamin D 
which causes a reactive increase of PTH secretion. In case 
of certain disorders, e.g., malignancies, the cut-off values 
higher than 50 nmol/L are required for optimal health 
benefits (e.g., 80 nmol/L). Epidemiological studies have 
indicated that hypovitaminosis D is associated with many 
disorders and malignancies (e.g., breast cancer, colon can-
cer, prostate cancer, leukemia), including both DM1 and 
DM2. In malignant disease, antiproliferative and prodif-
ferentiating properties of calcitriol are probably involved. 
Circulating 25OH D levels have been found to be associ-
ated with mortality (all-cause) in patients with terminal 
kidney diseases and coronary artery diseases. Also, sup-
plementation with vitamin D may reduce mortality. Nor-
malization and increase of 25-hydroxyvitamin D was 
associated with reduced risk for DM, cardiovascular dis-
eases and metabolic syndrome (26 ). Low vitamin D was 
linked to DM1 and also to insulin resistance in DM2 
(27-29). This can be explained by the role of 1,25-dihy-
droxyvitamin D on target cells of insulin action, i.e. the 
liver, skeletal muscles and adipose tissue. Apparently it 
can improve pancreatic b-cell function. Immunomodu-
lating function of 1,25-dihydroxyvitamin D might also 
be involved as it regulates immune cells and local immune 
response (30). The underlying mechanism in cardiovas-
cular diseases is that hypovitaminosis activates renin-
angiotensin system. In addition, vitamin D inhibits car-
diac muscle hypertrophy (31).
Regarding DM1 and hypovitaminosis D, there are 
moderate data indicating associations of low vitamin D 
and poor glycemic control and insulin resistance. Appar-
ently correction of hypovitaminosis D improves major 
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symptoms of DM1. Reasons for hypovitaminosis D in 
DM1 are multiple. Hypovitaminosis D observed in DM2 
is a consequence of increased adipose tissue and storage 
of vitamin D in adipocytes. In DM2 low vitamin D is 
associated with decreased insulin secretion and insulin 
resistance. Correction of hypovitaminosis D is associated 
with improvement of pancreatic insulin secretion and 
insulin sensitivity. Receptors for 1,25-dihydroxyvitamin 
D have been found on pancreatic cells, which further 
supports these observations. Therapy with vitamin D re-
stores insulin sensitivity in peripheral tissues through 
stimulation of its receptor expression. Several epidemio-
logical studies have reported on decreased 25-OH D and 
incidence of DM2 (6 ).
Vitamin D receptors are also found on skeletal muscle 
cells. Their action is performed through alteration of gene 
expression by DNA synthesis but also through a rapid 
action on membrane receptors. This is important as skel-
etal mass (or lean mass) has a profound effect on bone 
maintenance and bone formation. Conclusions of these 
studies do not suggest that vitamin D deficiency is re-
sponsible for occurrence and development of DM2, but 
point toward further investigations of metabolic associa-
tions (6 ).
In addition to the effect of hyperglycemia on bone 
quality in diabetes, bone mineralization may be due to 
impaired vitamin D and calcium metabolism. Increased 
blood glucose interferes with calcium reabsoprtion in the 
kidney. Patients with diabetes also suffer from hypovita-
minosis D (32, 33). DM2 patients are more likely to be 
vitamin D deficient, as their BMI is greater and this fat-
soluble vitamin might be stored in adipose tissue. A re-
cently published review by Madar et al. (34) demonstrat-
ed that currently there is insufficient evidence to 
recommend vitamin D supplementation in order to im-
prove glycemia or insulin resistance in patients with dia-
betes, normal fasting glucose, or impaired glucose toler-
ance (34, 35).
Available data on clinical research of interaction of 
bone and glucose metabolism are limited and further 
studies are urgently required to investigate the exact role 
of osteocalcin in energy balance in humans. This would 
include research to assess how therapies that modulate 
undercarboxylated osteocalcin synthesis may alter and 
improve glucose and lipid metabolism.
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